Merck partner Artiva blueprints San Diego R&D, manufacturing site to take NK cell operation to the next level
In January, Artiva Biotherapeutics CEO Fred Aslan said his company is looking to create CAR-NK therapies with best-in-class efficacy made in a wholly owned manufacturing process. Artiva is now another step closer to that goal.
Artiva will open a 52,000 square-foot headquarters in San Diego that will house its R&D and manufacturing of NK cell therapies. The site will have a multi-suite, custom-built manufacturing facility up to current GMP standards and adds to its current manufacturing operations at GC LabCell’s 300,000-square-foot location in South Korea. This new site won’t replace what’s going on in Korea but double down on the amount of capacity the company has.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.